LungLifeAI Logo
Menu
close
LungLifeAI coupleLungLifeAI couple

Early detection

is key

dots

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally.  Using a minimally invasive blood draw, our LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules.

Watch the Latest Videos from LungLife AI

How Our LungLB®'s Test is Saving Lives

Watch Video

Early Detection

Watch Video

Creating a Different Future

Watch Video
1 2 3 … 6
View All Videos

One in 16 people in the US will be diagnosed with lung cancer in their lifetime—and in many cases when it’s too late. We believe our simple blood test may afford those at risk a much better outcome through early diagnosis.”

Paul Pagano | CEO, LungLife AI

Our purpose
is simple

To be a driving force

To Be a Driving Force

in the early detection of lung cancer.

To achieve our purpose, we are dedicated to working collaboratively with scientific and clinical partners.

To achieve our purpose, we are

dedicated to working collaboratively

 with scientific and clinical partners.

Our LungLB® Test

Our LungLB® Test

is a blood-based tool that has been developed to provide clinicians the information needed to make informed decisions about the management of lung nodules and lung cancer. The test is performed in our CLIA certified laboratory in Thousand Oaks, California. 

Order a Test

Featured News

October 4, 2024

Options Cancellation and Re-issuance

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Remuneration Committee has decided to make amendments to the options issued to the Executive Directors at IPO in July 2021, and to those options issued to all current employees in 2021 or upon their appointment. Background and Rationale Under […]
• Read More
October 2, 2024

LungLB® analytical validation accepted for publication in peer-reviewed journal

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the acceptance for publication of data confirming analytical performance of the Company's blood-based LungLB® test in the journal BMC Pulmonary Medicine. Springer Nature's BMC Pulmonary Medicine is a globally recognised peer-reviewed medical journal with articles covering all aspects of the prevention, diagnosis and management of pulmonary and associated disorders. The […]
• Read More
1 2 3 … 34
LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
chevron-down